Cue Biopharma raises $30M in PIPE financing; sells shares, pre-funded warrants, and warrants

Also on November 14, 2022, the Company entered into a registration rights agreement (the “ Registration Rights Agreement ”) with the Investors, pursuant to which the Company agreed to register for resale the Shares, as well as the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants or the Warrants (the “ Warrant Shares ”).

On November 14, 2022, Cue Biopharma, Inc., a Delaware corporation (the “ Company ”), entered into securities purchase agreements (together, the “ Securities Purchase Agreement ”) with accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 7,656,966 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and, in lieu of Shares to certain investors, pre-funded warrants to purchase an aggregate of 1,531,440 shares of Common Stock (the “ Pre-Funded Warrants ”), and, in each case, accompanying warrants (the “ Warrants ”) to purchase an aggregate of up to 9,188,406 additional shares of Common Stock (or Pre-Funded Warrants to purchase Common Stock in lieu thereof) at a price of $3.265 per Share and accompanying Warrant (or $3.2649 per Pre-Funded Warrant and accompanying Warrant) (the “ Offering ”).